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Abstract
Background: Aspirin eugenol ester (AEE) is a promising drug candidate for treatment of inflammation, pain and fever
and prevention of cardiovascular diseases with less side effects. The experiment will be conducted to investigate the
efficacy of AEE on curing hyperlipidemia in Wistar rats. The rats were fed with high fat diet (HFD) for 8 weeks to induce
hyperlipidemia.
Results: Compared with the model group, the results showed that AEE at 54 mg/kg dosage could significantly decrease
the hyperlipidemia indexes including triglyceride (TG), low density lipoprotein (LDL) and total cholesterol (TCH) (p < 0.01),
increase high density lipoprotein (HDL) (p < 0.05) for five weeks drug administration. Meanwhile, simvastatin had same
effect on hyperlipidemia indexes such as TG, LDL, TC, but no significant increase in HDL.
Conclusion: AEE was effective against hyperlipidemia and had better anti-hyperlipidemic effect than its component,
acetylsalicylic acid (Aspirin, ASA), eugenol and integration of ASA and eugenol. Under the experimental circumstance,
the optimal dose of AEE to cure hyperlipidemia is 54 mg/kg for five weeks in Wistar rats.
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Background
Hyperlipidemia is a heterogeneous group of disorders
characterized by an excess of lipids in the bloodstream.
The concentrations of lipids, such as triglycerides (TG),
cholesterol (TCH) and low density lipoprotein (LDL)
increase, or the level of high density lipoprotein (HDL)
decrease in the blood [1]. Hyperlipidemia is becoming a
major health problem in the world recently even in
human and companion animal clinic [2, 3].
Acetylsalicylic acid (Aspirin, ASA) has been extended to
prevention and treatment of cardiovascular diseases [4–6].
Low-dose ASA (5 mg/kg) can ameliorate hyperlipidemia
induced by high-fat diet (HFD) and hyperinsulinemia in
Sprague–Dawley rats [7]. However, the side effects of ASA,
such as serious gastrointestinal damage, have limited the
long time using of this classic drug [8]. Eugenol is the main
component of volatile oil extracted from dry alabastrum
of Eugenia Caryophyllata Thumb. Eugenol has many
pharmacological activities, including antibacterial, anti-
inflammation, analgesia, analgesia, as well as anti-
oxidation [9], antiplatelet aggregation [10], and hyperlipid-
emia amelioration [11, 12]. However, the disadvantages of
irritation and vulnerablity to oxidation have limited the
application of eugenol in practice [13, 14].
To overcome the disadvantages of ASA and eugenol,
aspirin eugenol ester (AEE) as a novel medicinal compound
was designed and synthesized according to the prodrug
principles of structure recombination [15]. It is a pale
yellow and smellless crystal. The stomach, duodenum and
ileum showed an increased mucosa height after high-dose
AEE exposure (2000 mg · kg−1) in a 15-day oral dose tox-
icity study [16], this was mainly due to increased height of
the villus. The acute toxicity of AEE is less than that of
ASA and eugenol, only 0.02 times the toxicity of ASA and
0.27 times the toxicity of eugenol in mice [17]. AEE could
be metabolized into ASA and eugenol in vitro and in vivo
[18], and had the effects of anti-inflammation, antipyretic,
analgesia, and antioxidant [15, 19]. In addition, the
previous research indicated that AEE (50 mg · kg−1 and
160 mg · kg−1) could reduce the serum TC and TG in
rats with standard diet [16].
However, AEE as a promising drug candidate for pre-
venting and treating hyperlipidemia, it is important to
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characterize its efficacy in rats with HFD. The present
study was performed to assess the efficacy of AEE against
hyperlipidemia. Meanwhile, this study will provide guidance
for the design of further studies and clinical trials of AEE.
Results
Animal disease model
In regard to blood lipid levels, there was no significant
difference between Group I and Group II in week 4 and 6
(data not shown). So the administration time of HFD was
prolonged. At week 8, there were significant increase
of TG, LDL and TC and decrease of HDL of model
group (p < 0.01, seen in Table 1), which confirmed that
the hyperlipidemia animal model was successfully
established by HFD in the experiment.
Body weight
From the results of body weight before drug administra-
tion, blank group had a lower body weight than other
groups (P < 0.01, seen in Table 2), and this indicated that
HFD had a remakable influence on body weight. There
was no significant difference among other groups except
blank group. After drug administration, the average values
of body weight in drug treatment group were less than
model group and there was still significant difference
between blank and model group (P < 0.01). The average
body weight values in CMC-Na group were similar with
model group.
Anti-hyperlipidemic effect
Blood samples were taken for lipids examination after
the drugs were given for two weeks, but there was no
significant difference among groups (data not shown).
So the time was extended for five weeks. From table 3,
the difference effects of drugs on hyperlipidemia ap-
peared after AEE was given for five weeks. Meanwhile,
there was no statistical difference between model and
CMC-Na group, which indicated that CMC-Na has no
effect on hyperlipidemia indexes as a vehicle control.
In the blood lipid analysis (seen in Table 3), following five
weeks administration of drugs, TG, TC and LDL were sig-
nificantly decreased in varying degrees in comparison with
model group. These changes meant that there were signifi-
cant differences between the treated groups and the model
group at the end of 13th weeks. In regard to TG index, the
results in ASA and simvastatin groups were significantly
reduced when compared with model group (p < 0.01). With
the increase of AEE dose, the mean values of TG were
decreased which showed that TG values were dose-
dependent in AEE groups. Meanwhile, TG values in inte-
gration group also showed significant difference from
model group (p < 0.05). AEE at three different doses,
simvastatin, ASA, eugenol and integration of ASA and
eugenol reduced significantly levels of LDL and TC (p <
0.01) when compared with model group. HDL in model
group showed no significant difference from blank group
at week 13. Only AEE high dose group significantly in-
creased HDL (p < 0.05) when compared with model group.
Optimal dosage of AEE
The results demonstrated that AEE had significant effect
on ameliorative hyperlipidemia indexes. Through the evalu-
ation of AEE groups, high dose AEE could decrease more
significantly the levels of TG, TC, LDL (p < 0.01), and at the
same time increase HDL level (p < 0.05). The effects of
AEE at high, medium and low dose on LDL and TC were
similar (Figure 1). However, AEE at high dose had more
significant effect on TG (p < 0.01) and HDL (p < 0.05).
Multiple comparisons
Figure 2 showed the different effects of drugs on blood
lipid levels. When compared with ASA and eugenol
group, there was no significant difference between AEE
Table 1 Blood lipids level in Group I and II at the end of 8th week after using HFD diet
Variables Unit TG TCH HDL LDL
Group I mmol/L 0.77 ± 0.42 1.01 ± 0.25 0.55 ± 0.07 0.12 ± 0.08
Group II mmol/L 1.51 ± 0.38** 2.18 ± 0.31** 0.44 ± 0.06** 0.52 ± 0.08**
Note: TG: Triglyceride; HDL: High density lipoprotein; LDL: Low density lipoprotein; TCH: Total cholesterol. **P < 0.01 significant difference from blank group
Table 2 Body weights changes of rats before and after drug
treatment
Groups Body weight (g)
Before drug treatment Fifth week after drug treatment
A 276.1 ± 6.4aa 330.1 ± 5.6bb
B 295.4 ± 7.1 358.8 ± 7.2
C 298.4 ± 5.6 347.3 ± 6.8b
D 303.6 ± 7.3 340.8 ± 5.9bb
E 299.5 ± 6.9 340.8 ± 8.1 bb
F 301.1 ± 5.9 339.3 ± 6.4 bb
G 305.6 ± 6.9 343.4 ± 5.1 bb
H 292.6 ± 5.3 321.1 ± 5.9 bb
I 306.8 ± 5.9 342.4 ± 7.1 bb
J 302.7 ± 6.7 352.3 ± 6.6
Note: A: blank group, B: model group, C: AEE low dose, D: AEE medium dose,
E: AEE high dose, F: integration group (acetylsalicylic acid: eugenol, molar ratio
1:1, 0.11 mmol), G: acetylsalicylic acid group, H: eugenol group, I: simvastatin
group, J: CMC-Na group. aaP < 0.01 significant difference from model group
before administration. bP < 0.05, bbP < 0.01 significant difference from model
group after administration. The time before drug treatment was the end of
8th week after HFD diet was used and fifth week after drug treatment was the
end of 13th week after HFD diet was used
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and other groups, except the HDL index in AEE high dose
group (Fig. 2). However, when compared with integration
group, there was significant difference of LDL value in
AEE high dose group (p < 0.05) and HDL value in AEE
medium dose group (p < 0.05).
Compared with model group, AEE and simvastatin sig-
nificantly reduced TG, LDL and TC (p < 0.01). Meanwhile,
AEE increased significantly HDL (p < 0.05), but simvastatin
had no significant increase of HDL. The results showed
that simvastatin had stronger effect than low and medium
dose of AEE on TG and LDL value. From the results,
there was no statistical difference between simvastatin
and AEE high-dose groups, which suggested that the
anti-hyperlipidemic effects of high-dose AEE and sim-
vastatin were similar.
Discussion
Hyperlipidemia, a group of metabolic disorders character-
ized by the elevated levels of lipids, is a major modifiable
risk factor for atherosclerosis and cardiovascular disease
[20]. These lipids include cholesterol, cholesterol esters,
phospholipids, and triglycerides. Increased levels of LDL
are related to the development of atherosclerosis [21, 22].
HDL plays an important role in removing cholesterol
from tissues and protecting against cardiovascular disease.
Hyperlipidemia can be the result of an inherited disease in
certain breeds of dogs [23]. In pets, hyperlipidemia most
often occurs as a consequence of some disorder, hyperlip-
idemia even can also occur spontaneously after a meal of
high-fat foods, particularly table scraps [24, 25]. Hyperlip-
idemia is seen most commonly in ponies, miniature
horses, and donkeys, and less frequently in standard-
size adult horses [26, 27]. In non-ruminants, including
primates and man, hyperlipidemia may be increased
by dietary manipulations such as feeding excessive
cholesterol or fats with high saturated fatty acid con-
tent [28]. A great number of animal models, such pi-
geons, chickens, swine, cats, dogs, monkeys, mice,
rabbits and rats, have been tested [29]. Commonly
used rat strains (i.e. Sprague–Dawley, Wistar) typically
have high levels of HDL-C and low levels of LDL-C.
HFD is capable of promoting elevations in TC and
LDL in Sprague–Dawley or Wistar rats likely by redu-
cing bile acid production [30–32].
There are many chemical drugs that could ameliorate
hyperlipidemia such as: statins, fibrates, ezetimibe and nico-
tinic acid, but most of them are expensive and have
undesirable effect [33]. So there are increasing interest in
alternative drug for the prevention and treatment of hyper-
lipidemia. Currently available hyperlipidemic drugs have
been associated with a number of side effects. Therefore,
now it’s important to develop a novel drug that is less toxic,
Table 3 The blood lipids levels at the end of 13th week (after drugs administration for five weeks, n = 10)
Variables Blank Model CMC-Na Simvastatin AEE 18 AEE 36 AEE 54 Integration Aspirin Eugenol
TG 0.77 ± 0.2** 1.65 ± 0.22 1.63 ± 0.34 1.12 ± 0.15** 1.43 ± 0.11 1.36 ± 0.16* 1.23 ± 0.15** 1.35 ± 0.17* 1.27 ± 0.15** 1.39 ± 0.22
HDL 0.46 ± 0.04 0.52 ± 0.05 0.58 ± 0.02 0.56 ± 0.05 0.55 ± 0.04 0.56 ± 0.03 0.62 ± 0.05* 0.61 ± 0.02 0.61 ± 0.05 0.56 ± 0.01
LDL 0.11 ± 0.03** 0.54 ± 0.04 0.51 ± 0.05 0.23 ± 0.04** 0.31 ± 0.04** 0.3 ± 0.03** 0.25 ± 0.04** 0.31 ± 0.02** 0.30 ± 0.04** 0.28 ± 0.05**
TCH 1.01 ± 0.18** 2.49 ± 0.14 2.11 ± 0.38 1.61 ± 0.23** 1.82 ± 0.16** 1.73 ± 0.21** 1.55 ± 0.27** 1.77 ± 0.11** 1.80 ± 0.10** 1.68 ± 0.13**
Note: TG: Triglyceride; HDL: High density lipoprotein; LDL: Low density lipoprotein; TCH: Total cholesterol; Integration: acetylsalicylic acid:eugenol (molar ratio 1:1, 0.11 mmol).
The unit of TG, HDL, LDL and TC is mmol/L. *P< 0.05 significant difference from model group. **P< 0.01 significant difference from model group
Fig. 1 The influence of AEE different dosage on hyperlipemia indexes after administration for five weeks (n = 10). TG: Triglyceride; HDL: High
density lipoprotein; LDL: Low density lipoprotein; TCH: Total cholesterol. The blank group and AEE groups were used to compare with the model
group. aP < 0.05, aaP < 0.01 significant difference of HDL; bP < 0.05, bbP < 0.01 significant difference of LDL; cP < 0.05, ccP < 0.01 significant difference
of TG. dP < 0.05, ddP < 0.01 significant difference of TCH. There was no significant difference among three AEE groups in influence on
hyperlipidemia indexes
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less expensive, which can provide better safety and efficacy
on a long term usage.
In this study, the anti-hyperlipidaemic effects of AEE
were investigated in rats with induced hyperlipidemia by
HFD. The blood lipid indexes were observed during eight
weeks. When compared the lipid level between blank and
model group at week 8, there was a significant elevation in
the levels of serum LDL, TG and TC, and decrease of HDL.
Changed levels of these parameters in serum are presump-
tive markers of hyperlipidemia in serum. LDL is more
related to hyperlipidemia and is an important index in these
parameters. On other hand, HDL in this experiment
decreaseed at week 8 in model group. However, HDL
value in model group showed no significant difference
from blank group at week 13. This apparently unex-
pected result could be explained by the light increase
of HDL in model group and decrease in blank group,
some studies found that the diet content can effect
HDL level [34], light decrease of HDL in blank group
may due to the feeding long period rich of carbohy-
drate in standard diet. Some studies found that the
increased plasma apoE of apolipoproteins in aged
hyperlipidemia rats can increase HDL after a long
period [34–38].
From the result in this study, AEE had influence on blood
lipid indexes. The changes in TC, TG, LDL and HDL
confirmed that AEE had influence on hyperlipidemia.
Previous study on AEE showed that it had effect on TG
and TC [17]. Compared AEE high dose with simvastatin
and CMC-Na, it had positive effect on antihyperlipidemia.
AEE high dose significantly decreased TG, LDL, TC and
increased HDL index, but simvastatin has no significant
increase in HDL, this confirmed that AEE more benefit on
curing hyperlipidemia. Based on the results (Table 3), ASA
reduced TG significantly meanwhile eugenol had no signifi-
cant difference on TG, which may speculate that ASA may
play a key role on TG reduction from AEE. This may sug-
gest that the effects of simvastatin, AEE and its component
on LDL, TC were similar which decreased (p < 0.01) com-
pared with model group. On the other hand, CMC-Na as a
vehicle had no effect on hyperlipidemia, which confirmed
that the influence on hyperlipidemia is due to AEE only.
The previous study showed that eugenol had effect on
hyperlipidemia since it is probably mediated through inhib-
ition of hepatic cholesterol biosynthesis, reduction of lipid
absorption, enhanced catabolism of LDL-cholesterol, and
catabolism of TG [11, 12]. In our study, the results showed
that eugenol could reduce significantly the TG and TCH
index (Table 3 P < 0.01). However, there was no statistical
difference between eugenol and model group in the TG
index. Noteworthy, ASA could reduce TG, LDL and TCH
index (Table 3 P < 0.05), which showed that ASA possessed
Fig. 2 Effects of different drugs on hyperlipemia indexes after drugs administration for five weeks (n = 10). TG: Triglyceride; HDL: High density
lipoprotein; LDL: Low density lipoprotein; TCH: Total cholesterol. Integration: aspirin and eugenol at the mole ratio 1:1. aP < 0.05 significant
difference from aspirin group. aaP < 0.01 significant difference from aspirin group. bP < 0.05 significant difference from eugenol group. bbP < 0.01
significant difference from eugenol group. cP < 0.05 significant difference from integration group. ccP < 0.01 significant difference from integration
group. dP < 0.05 significant difference from simvastatin group. ddP < 0.01 significant difference from simvastatin group
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positive drug effects on hyperlipidemia. The study on the
metabolism of AEE showed that AEE was decomposed into
ASA and eugenol. Salicylic acid (SA) from AEE metabolism
as a final metabolite excreted in urine was coincided with
SA from ASA metabolism. However, the elimination time
of SA was longer than ASA, which might explain the effi-
cacy of AEE lasting longer than those of ASA and eugenol.
Therefore, the AEE effect on hyperlipidemia can come
mainly from eugenol and ASA, and the effect of AEE on
hyperlipidemia may result from synergetic action of ASA
and eugenol together, which could display stronger drug
effects than ASA and eugenol.
Conclusions
In summary, there were significant differences in blood
lipid indexes throughout the experimental period under the
present study conditions. For Wistar rats, the optimal dose
for curing hyperlipidemia was considered to be 54 mg/kg/
day administrating for five weeks, further studies should be
conducted to investigate its prevention effect and the action
mechanism of AEE on antihyperlipidemia.
Materials and methods
Chemicals and reagents
ASA eugenol ester (AEE), transparent crystal (purity:
99.5 % with RE-HPLC), was prepared in Key Lab of New
Animal Drug Project of Gansu Province, Key Lab of
Veterinary Drug Development of Agricultural Ministry,
Lanzhou Institute of Husbandry and Pharmaceutical
Sciences of CAAS. CMC-Na (carboxyl methyl cellulose
sodium) and simvastatin was supplied by Tianjin Chemical
Reagent Company (Tianjin, China). ASA and Tween-80
were supplied by Aladdin Industrial Corporation (Shanghai
China). Eugenol was supplied by Sinopharm Chemical
Reagent Co., Ltd. (Shanghai China). High diet feed (stand-
ard rat diet 77.8 %, yolk power 10 %, lard 10 %, cholesterol
2 %, bile salts 0.2 %) consists of 41.5 % lipids, 40.2 % carbo-
hydrates, and 18.3 % proteins (kcal) and standard rat diet
consists of 12.3 % lipids, 63.3 % carbohydrates, and 24.4 %
proteins (kcal). The feed was supplied from KeaoXieli Co.,
Ltd (Beijing, China). The TG, TC, LDL and HDL kits were
provided by Ningbo Medical System Biotechnology Co.,
Ltd (Ningbo, China). Erba XL-640 analyzer (German) was
used to measure the blood lipid level.
Animals
Wistar male rats with clean grade, aged 7 weeks and
weighing 160–180 g were purchased from the animal
breeding facilities of Lanzhou Army General Hospital
(Lanzhou, China). They were housed in plastic cages of
appropriate size (50 × 35 × 20 cm, ten rats per cage) with
stainless steel wire cover and chopped bedding. Light/dark
regimen was 12/12 h and living temperature was 22 ± 2 °C
with relative humidity of 55 ± 10 %. Rat feed and drinking
water were supplied ad libitum. The study was performed
in compliance with the Guidelines for the care and use of
laboratory animals as described in the US National Insti-
tutes of Health and approved by Institutional Animal Care
and Use Committee of Lanzhou Institute of Husbandry
and Pharmaceutical Science of CAAS. Animals were
allowed a 2-week quarantine and acclimation period prior
to start of the study.
Drug preparation
AEE, simvastatin and ASA suspension liquids were
prepared in 0.5 % of CMC-Na. Eugenol and Tween-80 at
the mass ratio of 1:2 mixed with the distilled water.
Group and dosing
After their arrival for two weeks, rats were randomized into
two main groups, group I as blank control (n = 10 rats) feed
with basal diet and group II (n = 90 rats) feed with HFD for
Table 4 The experimental design in the study
Groups Number of rats Food Drug Dosage Average volume per rat
A 10 Basal diet – – –
B 10 HFD diet – – –
C 10 HFD diet AEE 18 mg/kg 0.58 ml
D 10 HFD diet AEE 36 mg/kg 1.17 ml
E 10 HFD diet AEE 54 mg/kg 1.72 ml
F 10 HFD diet ASA+ Eugenol (20 + 18) mg/kg 1.19 ml
G 10 HFD diet ASA 20 mg/kg 0.65 ml
H 10 HFD diet Eugenol 18 mg/kg 0.54 ml
I 10 HFD diet Simvastatin 10 mg/kg 0.63 ml
J 10 HFD diet CMC-Na 20 mg/kg 1.28 ml
Note: HFD: high fat diet. A: blank group, B: model group, C:EE low dose, D: AEE medium dose, E: AEE high dose, F: integration group (ASA: eugenol, molar ratio 1:1),
G: acetylsalicylic acid (ASA) group, H: eugenol group, I: simvastatin group, J: CMC-Na group. At the end of 4th, 6th, 8th, 10th and 13th week after HFD was used,
the rats were fasted for 10–12 h and anesthetized with 10 % chloral hydrate. Approximately 1.5 ml blood samples were taken from tail tip for blood
lipids examination
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eight weeks. After hyperlipidemia were induced successfully
in rats, the HFD group was averagely divided into nine
groups and they were model group and eight treatment
groups. So it included eight test groups and two control
groups as blank and model groups (seen in Table 4).
The dosage for rats was based on individual weekly
body weights for five weeks. Drugs were administered
intragastrically to each rat. HFD continued during the
experiment period.
In order to compare AEE and its precursor, integration of
aspirin and eugenol group was designed in the experiment.
For the comparability of the results in the experiment, the
mole of medium-dose of AEE, aspirin, and eugenol is the
same as 0.11 mmol. The integration group administrated
both aspirin and eugenol, which were also designed at
0.11 mmol. The 0.5 % of CMC-Na at the dose of 4 ml · kg−1
was as the drug vehicle control and the dosage of CMC-Na
was close to equal in comparison with AEE and ASA
groups. Simvastatin (10 mg · kg−1) was choosed as positive
control drug to compare with AEE.
Blood sampling
After fasting for 10–12 h, rats were anesthetized with 10 %
chloral hydrate and blood samples were taken from tail tip
for blood lipids examination. In order to make sure the
volume of the blood sample, the rat tails were immersed in
water bath at 45 °C for 5 min to make the blood vessel
swelling, then approximately 1.5 ml blood sample was
collected from the rat tail. The serums were got through
centrifuge for 15 min at the speed of 4000 g at 4 °C.
Design of the experiment
First hyperlipidemia model disease is needed to be estab-
lished successfully by HFD. At the beginning of the experi-
ment, the rats were divided into two main groups. Group I
feed with standard diet and Group II feed with HFD. The
blood samples were taken on 4th, 6th and 8th week to
examine blood lipids. After the success of hyperlipidemia
animal model, Group II was divided into nine groups,
model group and eight treatment groups, and high fat diet
was continued during the rest experiment period.
After the administration of drug, blood samples were
taken to measure the change in blood lipids on 10th
week and 13th week. Blood sample was analyzed with
the same method.
Statistics
The statistical analyses were carried out using IBM SPSS
19.0 (USA). All data obtained from the experiment are
expressed as mean ± standard deviation (SD). The differ-
ence between Group I and Group II were evaluated by
Student’s t-Test. Statistical differences between the treat-
ments and the control were evaluated by using one-way
ANOVA with Duncan test. P-values less than 0.05 were
considered statistically significant.
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